Pharmacokinetics of Oral Recombinant Human Parathyroid Hormone [rhPTH(1–31)NH2] in Postmenopausal Women with Osteoporosis

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH2] in postmenopausal women with osteoporosis

(2012) K. Henriksen et al.   BONE

The Effects of Ronacaleret, a Calcium-Sensing Receptor Antagonist, on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women with Low Bone Mineral Density

(2011) Lorraine A. Fitzpatrick et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis

(2010) Julie Satterwhite et al.   CALCIFIED TISSUE INTERNATIONAL

PTH analogues and osteoporotic fractures

(2010) Harald JJ Verhaar et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials

(2010) M. A. Karsdal et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Parathyroid Hormone (1-34)-Coated Microneedle Patch System: Clinical Pharmacokinetics and Pharmacodynamics for Treatment of Osteoporosis

(2010) Peter E. Daddona et al.   PHARMACEUTICAL RESEARCH